Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | Number of treatments per 1,000 people |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Source
Release date
September 2019
More information
Region
France
Survey time period
2017
Special properties
general scheme, including mutual local sections
Supplementary notes
The source adds the following information: "Algorithm for defining the pathology: People with ALD (Long-Term Affection) in year n with ICD-10 dementia codes, and / or people who received at least 3 deliveries of drugs of the ATC classes (Anatomical, Therapeutic and Chemical classification) NO6DA and N06DX01 (update of January 27, 2015) during year n (at different dates), and / or people having received at least 3 drug deliveries classes NO6DA, N06DX01 (update of January 27, 2015) during year n-1 (at different dates), and / or people hospitalized for Alzheimer's disease or other dementias during years n to n- 4 (main diagnosis (PD) or related diagnosis (DR) of PMSIMCO), and / or people hospitalized during year n for any other reason with dementia as a complication or associated morbidity (associated diagnosis (DA) of PMSI- MCO), and / or people hospitalized s for Alzheimer's disease or other dementias in years n to n-4 (RIM-P PD) (excluding dementia linked to HIV infection and Parkinson's disease). "And" includes people with missing age ".
Citation formats
